唐君霞, 戴滋瀛, 潘婷婷, 陈永林, 周永宁, 关泉林. TEM1表达与胃癌患者新辅助化疗疗效相关性研究[J]. 中国肿瘤临床, 2019, 46(4): 173-177. DOI: 10.3969/j.issn.1000-8179.2019.04.353
引用本文: 唐君霞, 戴滋瀛, 潘婷婷, 陈永林, 周永宁, 关泉林. TEM1表达与胃癌患者新辅助化疗疗效相关性研究[J]. 中国肿瘤临床, 2019, 46(4): 173-177. DOI: 10.3969/j.issn.1000-8179.2019.04.353
shu
Tang Junxia, Dai Ziying, Pan Tingting, Chen Yonglin, Zhou Yongning, Guan Quanlin. Correlation between TEM1 expression and efficacy of neoadjuvant chemotherapy in patients with gastric cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(4): 173-177. DOI: 10.3969/j.issn.1000-8179.2019.04.353
Citation: Tang Junxia, Dai Ziying, Pan Tingting, Chen Yonglin, Zhou Yongning, Guan Quanlin. Correlation between TEM1 expression and efficacy of neoadjuvant chemotherapy in patients with gastric cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(4): 173-177. DOI: 10.3969/j.issn.1000-8179.2019.04.353
shu

TEM1表达与胃癌患者新辅助化疗疗效相关性研究

Correlation between TEM1 expression and efficacy of neoadjuvant chemotherapy in patients with gastric cancer

    摘要
  • 摘要:
      目的  检测胃癌组织中P53、人表皮生长因子受体2（HER-2）、肿瘤内皮标记物1（TEM1）的表达情况，结合新辅助化疗后临床疗效进行相关性分析，探讨其作为新辅助化疗疗效生物学标志物的可能性。
      方法  选取2015年5月至2017年5月于兰州大学第一医院就诊以氟尿嘧啶为基础行新辅助化疗的63例胃癌患者，对新辅助化疗前的胃癌标本行免疫组织化学法检测P53、HER- 2、TEM1的表达情况，通过影像学评估新辅助化疗疗效，分析各肿瘤指标与新辅助化疗疗效之间的关系。
      结果  63例进展期胃癌患者新辅助化疗后总有效率为69.8%，其中完全缓解（complete response，CR）2例，部分缓解（partial response，PR）7例，疾病稳定（stable disease，SD）35例，疾病进展（progressive disease，PD）19例；单因素分析结果显示TEM1阳性、T分期较高的患者新辅助化疗疗效较差（均P < 0.05）；病变部位、分化程度、病灶大小、P53（P=0.488）阳性及HER-2（P=0.106）阳性表达与胃癌新辅助化疗疗效无相关。多因素分析结果显示TEM1阳性、T分期高可能是进展期胃癌患者新辅助化疗疗效差的预测因素。
      结论  TEM1作为肿瘤基质的标志物，其阳性表达可能成为预测胃癌新辅助化疗疗效差的重要分子生物学指标。

     

    Abstract:
      Objective  To detect the expression of P53, human epidermal growth factor receptor-2 (HER-2), and tumor endothelial marker 1 (TEM1) in gastric cancer tissues, analyze their correlation with clinical efficacy, and explore their potential roles as biomarkers for neoadjuvant chemotherapy.
      Methods  Sixty-three patients with gastric cancer who underwent fluorouracil-based neoadjuvant chemotherapy in The First Hospital of Lanzhou University from May 2015 to May 2017 were enrolled. Using immunohistochemistry, the expression of P53, Her2, and TEM1 was detected in 63 gastric cancer specimens before neoadjuvant chemotherapy. The efficacy of neoadjuvant chemotherapy was assessed by imaging. The relationship between the expression of P53, HER-2, and TEM1 and the efficacy of neoadjuvant chemotherapy was analyzed.
      Results  The total effective rate of neoadjuvant chemotherapy in 63 patients with advanced gastric cancer was 69.8%, with 2, 7, and 35 patients achieving complete remission, partial remission, and stable disease, respectively. Disease progression was noted in 19 patients. Univariate analysis revealed that patients positive for TEM1 and having high T stage had a poor response to neoadjuvant chemotherapy (P < 0.05); furthermore, location, differentiation, and size of tumor; P53 positivity (P=0.488); and Her-2 positivity (P=0.106) were not associated with the efficacy of neoadjuvant chemotherapy for gastric cancer. Multivariate analysis revealed that TEM1 positivity and a higher T stage could be factors that predicted the response to neoadjuvant chemotherapy in patients with advanced gastric cancer.
      Conclusions  TEM1, as a marker of tumor stroma, may be an important molecular biological indicator that predicts the poor response to neoadjuvant chemotherapy in patients with gastric cancer.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回